NCT07839936: A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
- State
- Under way
- Phase
- Phase 2
- People
- 175 planned
- Started
- 24 Sep 2026
- Primary completion
- Aug 2028
- Arms
- VERVE-102 Dose 1, VERVE-102 Dose 2, VERVE-102 Dose 3
- Results
- None posted
- 24 Sep 2026: Trial registered
- 24 Sep 2026: Trial started